Lymphatic vessel density as a prognostic indicator in Asian NSCLC patients: a meta-analysis

Xu, Shuanglan; Yang, Jiao; Xu, Shuangyan; Zhu, Yun; Zhang, Chunfang; Liu, Liqiong; Líu, Hao; Dong, Yue; Teng, Zhaowei; Xing, Xin

doi:10.1186/s12890-018-0702-9

Cited by 5 publications

(4 citation statements)

References 40 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Lymphatic vascular density (LVD) is used as an evaluation index for lymphangiogenesis [ 34 ], in addition, various LECs-specific endothelial markers have been used to evaluate tumor-associated lymphangiogenesis by immunohistochemical methods, including Prox-1 [ 34 ], VEGFR-3 [ 35 , 36 ], LVYE-1 [ 37 ], Podoplanin [ 34 ], D2-40 [ 38 , 39 ], NRP-2 [ 40 ] and others (Fig. 1).…”

Section: Lymphatic Vascular Markersmentioning

confidence: 99%

“…Peritumor had higher VEGF-C and VEGF-D expression and were associated with more advanced regional LNM [ 35 ]. In lung adenocarcinoma (LUAD), LVD is higher in the tumor stroma of PNPD + tissue [ 34 ], while in lung squamous cell carcinoma (LSCC), podoplanin does not promote cell migration, but also down-regulates VEGF-C by regulating JNK pathway [ 35 ]. Many markers affecting LNM in NSCLC were also associated with clinicopathological factors and prognosis (Table 1 ).…”

Section: Lymphatic Vascular Markersmentioning

confidence: 99%

See 1 more Smart Citation

Advances in lymphatic metastasis of non-small cell lung cancer

Zhang,

Ma,

Xue

et al. 2024

Cell Commun Signal

View full text Add to dashboard Cite

Lung cancer is a deeply malignant tumor with high incidence and mortality. Despite the rapid development of diagnosis and treatment technology, abundant patients with lung cancer are still inevitably faced with recurrence and metastasis, contributing to death. Lymphatic metastasis is the first step of distant metastasis and an important prognostic indicator of non-small cell lung cancer. Tumor-induced lymphangiogenesis is involved in the construction of the tumor microenvironment, except promoting malignant proliferation and metastasis of tumor cells, it also plays a crucial role in individual response to treatment, especially immunotherapy. Thus, this article reviews the current research status of lymphatic metastasis in non-small cell lung cancer, in order to provide some insights for the basic research and clinical and translational application in this field.

show abstract

Section: Lymphatic Vascular Markersmentioning

confidence: 99%

Section: Lymphatic Vascular Markersmentioning

confidence: 99%

Advances in lymphatic metastasis of non-small cell lung cancer

Zhang,

Ma,

Xue

et al. 2024

Cell Commun Signal

View full text Add to dashboard Cite

show abstract

“…65 Multiple investigations give attention to the ITLs and PTLs, and their role in malignancy development and progression. Interestingly, Lymphovascular invasion (LVI) [66][67][68][69] and high LVDs [70][71][72] could be strongly prognostic factor for tumor aggressiveness and an indicator of occult metastases in several malignancies, including UCB as well, 13,73,74 while some retrospective analysis however controversially indicated LVDs is not associated with survival in various cancer in statistics (e.g., melanoma, breast cancer), thus, more research is needed in this part.…”

Section: The Specific Biomarkers and Growth Factors For Lymphatic Sysmentioning

confidence: 99%

<p>Communication Of Cancer Cells And Lymphatic Vessels In Cancer: Focus On Bladder Cancer</p>

Wu¹,

Ding²,

Cai³

et al. 2019

OTT

View full text Add to dashboard Cite

Bladder cancer is one of the most commonly diagnosed cancers worldwide and causes the highest lifetime treatment costs per patient. Bladder cancer is most likely to metastasize through lymphatic ducts, and once the lymph nodes are involved, the prognosis is poorly and finitely improved by current modalities. The underlying metastatic mechanism for bladder cancer is thus becoming a research focus to date. To identify relevant published data, an online search of the PubMed/Medline archives was performed to locate original articles and review articles regarding lymphangiogenesis and lymphatic metastasis in urinary bladder cancer (UBC), and was limited to articles in English published between 1998 and 2018. A further search of the clinical trials.gov search engine was conducted to identify both trials with results available and those with results not yet available. Herein, we summarized the unique mechanisms and biomarkers involved in the malignant progression of bladder cancer as well as their emerging roles in therapeutics, and that current data suggests that lymphangiogenesis and lymph node invasion are important prognostic factors for UBC. The growing knowledge about their roles in bladder cancers provides the basis for novel therapeutic strategies. In addition, more basic and clinical research needs to be conducted in order to identify further accurate predictive molecules and relevant mechanisms.

show abstract

“…This underscores the need to unravel events underlying tumorigenesis of NSCLC. The most common form of NSCLC metastasis is lymph node metastasis [ 3 ]. Research shows that Lymph node metastasis is the most important factor affecting the prognosis of primary lung cancer [ 4 ].…”

Section: Introductionmentioning

confidence: 99%

Genomic Landscape of Metastatic Lymph Nodes and Primary Tumors in Non-Small-Cell Lung Cancer

Chen

Zhang³

et al. 2022

Pathol. Oncol. Res.

View full text Add to dashboard Cite

Objective: To investigate the genetic mutation characteristics of non-small cell lung cancers (NSCLC) with and without lymph node metastasis.Methods: Primary lesions and metastatic lymph node lesions of 36 Chinese NSCLC patients were tested for somatic mutations, tumor mutation burden, phylogenetic and clonal evolutional analysis using a 1021-gene panel by next-generation sequencing (NGS) with an average sequencing depth of 671X.Results: In this study, eighteen patients with lung adenocarcinoma (LUAD) and 18 with lung squamous cell carcinoma (LUSC) were included. Different groups had distinct characteristics of gene mutations. CTNNB1 gene mutations were only present in Nome_LC LUAD patients (p < 0.05). ARID1A mutation was however the only gene with significant alterations (p < 0.05) in Nome_LC in LUSC. Phylogenetic trees of mutated genes were also constructed. Linear and parallel evolutions of metastatic lymph nodes were observed both in LUAD and LUSC.Conclusion: LUSC exhibited more genetic mutations than LUAD. Intriguingly, there was significant difference in gene mutations between Meta_LC and Nome_LC. CTNNB1 gene alteration was the key mutation in LUAD that seems to promote proliferation of the tumor and then determine T stage. On the other hand, proliferation of the tumor was characterized by ARID1A missense mutation in LUSC, thus influencing the T stage as well. Lymph node metastasis could display both linear and parallel evolutionary characteristics in NSCLC. Different metastatic lymph nodes might have exactly the same or different mutated genes, underlining the heterogeneous genomic characteristics of these cancer types.

show abstract

Lymphatic vessel density as a prognostic indicator in Asian NSCLC patients: a meta-analysis

Cited by 5 publications

References 40 publications

Advances in lymphatic metastasis of non-small cell lung cancer

Advances in lymphatic metastasis of non-small cell lung cancer

<p>Communication Of Cancer Cells And Lymphatic Vessels In Cancer: Focus On Bladder Cancer</p>

Genomic Landscape of Metastatic Lymph Nodes and Primary Tumors in Non-Small-Cell Lung Cancer

Contact Info

Product

Resources

About